In short
There is currently 1 ongoing clinical trial investigating treatment options for pulmonary venous thrombosis. This trial is exploring whether Rosuvastatin, a medication commonly used to lower cholesterol, can help reduce the risk of recurrent blood clots in patients who have experienced deep vein thrombosis or pulmonary embolism. The study is being conducted in France and Norway.
Clinical trial locations
- France
- Norway
Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism
This clinical trial is investigating whether Rosuvastatin Calcium can help prevent recurrent blood clots in patients who have already experienced certain types of clotting conditions. The study focuses on patients with pulmonary embolism, venous thromboembolism, and deep vein thrombosis.
Main inclusion criteria: Patients eligible for this study must have a confirmed diagnosis of a symptomatic blood clot in the deep veins of the upper leg (proximal deep vein thrombosis) or a blockage in the lung's arteries (pulmonary embolism) that occurred within the last 30 days. The diagnosis must be confirmed and the patient must be showing symptoms of the condition. Both male and female patients can participate.
Main exclusion criteria: Patients cannot participate if they are pregnant or breastfeeding, have a history of severe allergic reactions to the study medication, or are currently taking medications that might interfere with the study drug. Those with severe liver or kidney disease, recent significant bleeding problems, recent major surgery, or uncontrolled high blood pressure are also excluded. Additionally, individuals with a history of alcohol or drug abuse, certain uncontrolled heart rhythm problems, or those unable to follow study procedures are not eligible.
Study focus and goals: The trial aims to determine whether taking Rosuvastatin Calcium can lower the rate of major blood clot events in patients who have already experienced a clot. Participants will be randomly assigned to receive either the active medication or a placebo (an inactive substance with no medication). Throughout the study, researchers will monitor participants to observe any differences in the recurrence of blood clots between the two groups. The study will also look at other health outcomes, such as post-thrombotic syndrome (a condition that can develop after a blood clot), as well as other vascular events like heart attacks or strokes. The trial is expected to continue until the end of 2027.
Investigational drug: Rosuvastatin Calcium is the medication being tested in this trial. It is a type of statin commonly used to lower cholesterol levels in the blood. In this study, it is being tested at a dose of 20 mg in tablet form for its potential benefits in preventing further blood clot events. The medication works by inhibiting an enzyme involved in cholesterol production in the liver, which may also help reduce inflammation and stabilize blood vessel walls.
Summary
Currently, there is only one active clinical trial focused on pulmonary venous thrombosis and related blood clotting conditions. This trial is being conducted in two European countries, France and Norway, and is exploring a novel use of Rosuvastatin, a medication traditionally used for cholesterol management. The study represents an important investigation into whether statins might offer additional benefits beyond their known cholesterol-lowering effects, specifically in preventing recurrent blood clots in patients who have already experienced deep vein thrombosis or pulmonary embolism. With an expected completion date at the end of 2027, this research may provide valuable insights into new preventive strategies for patients at risk of recurrent venous thromboembolism.
